QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
Title of each class | Trading symbol(s) | Name of each exchange on which registered |
☒ | Accelerated filer | ☐ | ||||
Non-accelerated filer | ☐ | Smaller reporting company | ||||
Emerging growth company |
Page Numbers | ||
Item 1. | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 1. | ||
Item 1a. | ||
Item 6. | ||
• | the ongoing COVID-19 pandemic and measures intended to prevent its spread, including the impact on our tenants, operators and Senior Housing - Managed communities (as defined below); |
• | our dependence on the operating success of our tenants; |
• | the potential variability of our reported rental and related revenues following the adoption of Topic 842 (as defined below) on January 1, 2019; |
• | operational risks with respect to our Senior Housing - Managed communities; |
• | the effect of our tenants declaring bankruptcy or becoming insolvent; |
• | our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties; |
• | the impact of litigation and rising insurance costs on the business of our tenants; |
• | the possibility that Sabra may not acquire the remaining majority interest in the Enlivant Joint Venture (as defined below); |
• | risks associated with our investments in joint ventures; |
• | changes in healthcare regulation and political or economic conditions; |
• | the impact of required regulatory approvals of transfers of healthcare properties; |
• | competitive conditions in our industry; |
• | our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries; |
• | the significant amount of and our ability to service our indebtedness; |
• | covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms; |
• | increases in market interest rates; |
• | the potential phasing out of the London Interbank Offered Rate (“LIBOR”) benchmark after 2021; |
• | our ability to raise capital through equity and debt financings; |
• | changes in foreign currency exchange rates; |
• | the relatively illiquid nature of real estate investments; |
• | the loss of key management personnel; |
• | uninsured or underinsured losses affecting our properties and the possibility of environmental compliance costs and liabilities; |
• | the impact of a failure or security breach of information technology in our operations; |
• | our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws; |
• | changes in tax laws and regulations affecting REITs (including the potential effects of the Tax Cuts and Jobs Act); |
• | compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; and |
• | the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities. |
ITEM 1. | FINANCIAL STATEMENTS |
March 31, 2020 | December 31, 2019 | ||||||
(unaudited) | |||||||
Assets | |||||||
Real estate investments, net of accumulated depreciation of $569,752 and $539,213 as of March 31, 2020 and December 31, 2019, respectively | $ | $ | |||||
Loans receivable and other investments, net | |||||||
Investment in unconsolidated joint venture | |||||||
Cash and cash equivalents | |||||||
Restricted cash | |||||||
Lease intangible assets, net | |||||||
Accounts receivable, prepaid expenses and other assets, net | |||||||
Total assets | $ | $ | |||||
Liabilities | |||||||
Secured debt, net | $ | $ | |||||
Revolving credit facility | |||||||
Term loans, net | |||||||
Senior unsecured notes, net | |||||||
Accounts payable and accrued liabilities | |||||||
Lease intangible liabilities, net | |||||||
Total liabilities | |||||||
Commitments and contingencies (Note 13) | |||||||
Equity | |||||||
Preferred stock, $.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2020 and December 31, 2019 | |||||||
Common stock, $.01 par value; 250,000,000 shares authorized, 205,559,356 and 205,208,018 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively | |||||||
Additional paid-in capital | |||||||
Cumulative distributions in excess of net income | ( | ) | ( | ) | |||
Accumulated other comprehensive loss | ( | ) | ( | ) | |||
Total equity | |||||||
Total liabilities and equity | $ | $ |
Three Months Ended March 31, | |||||||
2020 | 2019 | ||||||
Revenues: | |||||||
Rental and related revenues | $ | $ | |||||
Interest and other income | |||||||
Resident fees and services | |||||||
Total revenues | |||||||
Expenses: | |||||||
Depreciation and amortization | |||||||
Interest | |||||||
Triple-net portfolio operating expenses | |||||||
Senior housing - managed portfolio operating expenses | |||||||
General and administrative | |||||||
Provision for loan losses and other reserves | |||||||
Impairment of real estate | |||||||
Total expenses | |||||||
Other income (expense): | |||||||
Other income | |||||||
Net loss on sales of real estate | ( | ) | ( | ) | |||
Total other income (expense) | ( | ) | |||||
Income (loss) before loss from unconsolidated joint venture and income tax expense | ( | ) | |||||
Loss from unconsolidated joint venture | ( | ) | ( | ) | |||
Income tax expense | ( | ) | ( | ) | |||
Net income (loss) | ( | ) | |||||
Net income attributable to noncontrolling interest | ( | ) | |||||
Net income (loss) attributable to common stockholders | $ | $ | ( | ) | |||
Net income (loss) attributable to common stockholders, per: | |||||||
Basic common share | $ | $ | ( | ) | |||
Diluted common share | $ | $ | ( | ) | |||
Weighted-average number of common shares outstanding, basic | |||||||
Weighted-average number of common shares outstanding, diluted |
Three Months Ended March 31, | |||||||
2020 | 2019 | ||||||
Net income (loss) | $ | $ | ( | ) | |||
Other comprehensive income (loss): | |||||||
Unrealized gain (loss), net of tax: | |||||||
Foreign currency translation gain (loss) | ( | ) | |||||
Unrealized loss on cash flow hedges | ( | ) | ( | ) | |||
Total other comprehensive loss | ( | ) | ( | ) | |||
Comprehensive loss | ( | ) | ( | ) | |||
Comprehensive income attributable to noncontrolling interest | ( | ) | |||||
Comprehensive loss attributable to Sabra Health Care REIT, Inc. | $ | ( | ) | $ | ( | ) |
Three Months Ended March 31, 2019 | |||||||||||||||||||||||||||||||
Common Stock | Additional Paid-in Capital | Cumulative Distributions in Excess of Net Income | Accumulated Other Comprehensive Income (Loss) | Total Stockholders’ Equity | Noncontrolling Interest | Total Equity | |||||||||||||||||||||||||
Shares | Amounts | ||||||||||||||||||||||||||||||
Balance, December 31, 2018 | $ | $ | $ | ( | ) | $ | $ | $ | $ | ||||||||||||||||||||||
Cumulative effect of Topic 842 adoption | — | — | — | ( | ) | — | ( | ) | — | ( | ) | ||||||||||||||||||||
Net (loss) income | — | — | — | ( | ) | — | ( | ) | ( | ) | |||||||||||||||||||||
Other comprehensive loss | — | — | — | — | ( | ) | ( | ) | — | ( | ) | ||||||||||||||||||||
Distributions to noncontrolling interest | — | — | — | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||
Amortization of stock-based compensation | — | — | — | — | — | ||||||||||||||||||||||||||
Common stock issuance, net | ( | ) | — | — | ( | ) | — | ( | ) | ||||||||||||||||||||||
Common dividends ($0.45 per share) | — | — | — | ( | ) | — | ( | ) | — | ( | ) | ||||||||||||||||||||
Balance, March 31, 2019 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
Three Months Ended March 31, 2020 | |||||||||||||||||||||||||||||||
Common Stock | Additional Paid-in Capital | Cumulative Distributions in Excess of Net Income | Accumulated Other Comprehensive Income (Loss) | Total Stockholders’ Equity | Noncontrolling Interest | Total Equity | |||||||||||||||||||||||||
Shares | Amounts | ||||||||||||||||||||||||||||||
Balance, December 31, 2019 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
Cumulative effect of Topic 326 adoption | — | — | — | ( | ) | — | ( | ) | — | ( | ) | ||||||||||||||||||||
Net income | — | — | — | — | — | ||||||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | ( | ) | ( | ) | — | ( | ) | ||||||||||||||||||||
Amortization of stock-based compensation | — | — | — | — | — | ||||||||||||||||||||||||||
Common stock issuance, net | — | — | — | ||||||||||||||||||||||||||||
Common dividends ($0.45 per share) | — | — | — | ( | ) | — | ( | ) | — | ( | ) | ||||||||||||||||||||
Balance, March 31, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
Three Months Ended March 31, | |||||||
2020 | 2019 | ||||||
Cash flows from operating activities: | |||||||
Net income (loss) | $ | $ | ( | ) | |||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||
Depreciation and amortization | |||||||
Non-cash rental and related revenues | ( | ) | ( | ) | |||
Non-cash interest income | ( | ) | ( | ) | |||
Non-cash interest expense | |||||||
Stock-based compensation expense | |||||||
Provision for loan losses and other reserves | |||||||
Net loss on sales of real estate | |||||||
Impairment of real estate | |||||||
Loss from unconsolidated joint venture | |||||||
Distributions of earnings from unconsolidated joint venture | |||||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable, prepaid expenses and other assets, net | ( | ) | ( | ) | |||
Accounts payable and accrued liabilities | ( | ) | ( | ) | |||
Net cash provided by operating activities | |||||||
Cash flows from investing activities: | |||||||
Acquisition of real estate | ( | ) | |||||
Origination and fundings of loans receivable | ( | ) | ( | ) | |||
Additions to real estate | ( | ) | ( | ) | |||
Repayments of loans receivable | |||||||
Repayments of preferred equity investments | |||||||
Net proceeds from the sales of real estate | |||||||
Net cash (used in) provided by investing activities | ( | ) | |||||
Cash flows from financing activities: | |||||||
Net borrowings from (repayments of) revolving credit facility | ( | ) | |||||
Principal payments on secured debt | ( | ) | ( | ) | |||
Payments of deferred financing costs | ( | ) | ( | ) | |||
Distributions to noncontrolling interest | ( | ) | |||||
Issuance of common stock, net | ( | ) | |||||
Dividends paid on common stock | ( | ) | ( | ) | |||
Net cash provided by (used in) financing activities | ( | ) | |||||
Net increase (decrease) in cash, cash equivalents and restricted cash | ( | ) | |||||
Effect of foreign currency translation on cash, cash equivalents and restricted cash | ( | ) | |||||
Cash, cash equivalents and restricted cash, beginning of period | |||||||
Cash, cash equivalents and restricted cash, end of period | $ | $ | |||||
Supplemental disclosure of cash flow information: | |||||||
Interest paid | $ | $ | |||||
Supplemental disclosure of non-cash investing activities: | |||||||
Decrease in loans receivable and other investments due to acquisition of real estate | $ | ( | ) | $ |
• | Decreased occupancy and increased operating costs for the Company’s tenants and borrowers, which may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to the Company. In some cases, the Company may have to restructure tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to the Company as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of the Company’s investments are not recoverable, which could result in an impairment charge. |
• | Decreased occupancy and increased operating costs within the Company’s Senior Housing - Managed portfolio and in the Company’s |
Three Months Ended March 31, | ||||
2020 | ||||
Land | $ | |||
Building and improvements | ||||
Tenant origination and absorption costs intangible assets | ||||
Tenant relationship intangible assets | ||||
Total consideration | $ |
Property Type | Number of Properties | Number of Beds/Units | Total Real Estate at Cost | Accumulated Depreciation | Total Real Estate Investments, Net | |||||||||||||
Skilled Nursing/Transitional Care | $ | $ | ( | ) | $ | |||||||||||||
Senior Housing - Leased | ( | ) | ||||||||||||||||
Senior Housing - Managed | ( | ) | ||||||||||||||||
Specialty Hospitals and Other | ( | ) | ||||||||||||||||
( | ) | |||||||||||||||||
Corporate Level | ( | ) | ||||||||||||||||
$ | $ | ( | ) | $ |
Property Type | Number of Properties | Number of Beds/Units | Total Real Estate at Cost | Accumulated Depreciation | Total Real Estate Investments, Net | |||||||||||||
Skilled Nursing/Transitional Care | $ | $ | ( | ) | $ | |||||||||||||
Senior Housing - Leased | ( | ) | ||||||||||||||||
Senior Housing - Managed | ( | ) | ||||||||||||||||
Specialty Hospitals and Other | ( | ) | ||||||||||||||||
( | ) | |||||||||||||||||
Corporate Level | ( | ) | ||||||||||||||||
$ | $ | ( | ) | $ |
March 31, 2020 | December 31, 2019 | ||||||
Building and improvements | $ | $ | |||||
Furniture and equipment | |||||||
Land improvements | |||||||
Land | |||||||
Accumulated depreciation | ( | ) | ( | ) | |||
$ | $ |
April 1 through December 31, 2020 | $ | ||
2021 | |||
2022 | |||
2023 | |||
2024 | |||
Thereafter | |||
$ | |||
March 31, 2020 | |||||||||||||||||||||||||
Investment | Quantity as of March 31, 2020 | Property Type | Principal Balance as of March 31, 2020 (1) | Book Value as of March 31, 2020 | Book Value as of December 31, 2019 | Weighted Average Contractual Interest Rate / Rate of Return | Weighted Average Annualized Effective Interest Rate / Rate of Return | Maturity Date as of March 31, 2020 | |||||||||||||||||
Loans Receivable: | |||||||||||||||||||||||||
Mortgage | Specialty Hospital | $ | $ | $ | % | % | 01/31/27 | ||||||||||||||||||
Construction | Senior Housing | % | % | 09/30/22 | |||||||||||||||||||||
Other | Multiple | % | % | 09/01/20- 08/31/28 | |||||||||||||||||||||
% | % | ||||||||||||||||||||||||
Allowance for loan losses | — | ( | ) | ( | ) | ||||||||||||||||||||
$ | $ | $ | |||||||||||||||||||||||
Other Investments: | |||||||||||||||||||||||||
Preferred Equity | Skilled Nursing / Senior Housing | % | % | N/A | |||||||||||||||||||||
Total | $ | $ | $ | % | % | ||||||||||||||||||||
(1) | Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees. |
Three Months Ended March 31, | ||||||||
2020 | 2019 | |||||||
Accretable yield, beginning of period | $ | $ | ||||||
Accretion recognized in earnings | ( | ) | ( | ) | ||||
Reduction due to payoff | ( | ) | ||||||
Accretable yield, end of period | $ | $ | ||||||
Interest Rate Type | Principal Balance as of March 31, 2020 (1)(2) | Principal Balance as of December 31, 2019 (1) | Weighted Average Interest Rate at March 31, 2020 (3) | Maturity Date | ||||||||
Fixed Rate | $ | $ | % | December 2021 - August 2051 |
(1) | Principal balance does not include deferred financing costs, net of $ |
(2) | Excludes $ |
(3) | Weighted average interest rate includes private mortgage insurance. |
Principal Balance as of | ||||||||||
Title | Maturity Date | March 31, 2020 (1) | December 31, 2019 (1) | |||||||
4.80% senior unsecured notes due 2024 (“2024 Notes”) | June 1, 2024 | $ | $ | |||||||
5.125% senior unsecured notes due 2026 (“2026 Notes”) | August 15, 2026 | |||||||||
5.88% senior unsecured notes due 2027 (“2027 Notes”) | May 17, 2027 | |||||||||
3.90% senior unsecured notes due 2029 (“2029 Notes”) | October 15, 2029 | |||||||||
$ | $ | |||||||||
(1) | Principal balance does not include premium, net of $ |
Secured Indebtedness (1) | Revolving Credit Facility (2) | Term Loans | Senior Notes | Total | ||||||||||||||||
April 1 through December 31, 2020 | $ | $ | $ | $ | $ | |||||||||||||||
2021 | ||||||||||||||||||||
2022 | ||||||||||||||||||||
2023 | ||||||||||||||||||||
2024 | ||||||||||||||||||||
Thereafter | ||||||||||||||||||||
Total Debt | ||||||||||||||||||||
Premium, net | ||||||||||||||||||||
Deferred financing costs, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Total Debt, Net | $ | $ | $ | $ | $ |
(1) | Excludes $ |
(2) | Revolving Credit Facility is subject to |
March 31, 2020 | December 31, 2019 | |||||||
Derivatives designated as cash flow hedges: | ||||||||
Denominated in U.S. Dollars (1) | $ | $ | ||||||
Denominated in Canadian Dollars (2) | $ | $ | ||||||
Derivatives designated as net investment hedges: | ||||||||
Denominated in Canadian Dollars | $ | $ | ||||||
Financial instrument designated as net investment hedge: | ||||||||
Denominated in Canadian Dollars | $ | $ | ||||||
Derivatives not designated as net investment hedges: | ||||||||
Denominated in Canadian Dollars | $ | $ | ||||||
(2) | Balance as of March 31, 2020 includes |
Count as of March 31, 2020 | Fair Value | Maturity Dates | |||||||||||||||
Type | Designation | March 31, 2020 | December 31, 2019 | Balance Sheet Location | |||||||||||||
Assets: | |||||||||||||||||
Interest rate swaps | Cash flow | $ | $ | N/A | Accounts receivable, prepaid expenses and other assets, net | ||||||||||||
Forward starting interest rate swaps | Cash flow | 2034 | Accounts receivable, prepaid expenses and other assets, net | ||||||||||||||
Cross currency interest rate swaps | Net investment | 2025 | Accounts receivable, prepaid expenses and other assets, net | ||||||||||||||
$ | $ | ||||||||||||||||
Liabilities: | |||||||||||||||||
Interest rate swaps | Cash flow | $ | $ | 2020-2023 | Accounts payable and accrued liabilities | ||||||||||||
Forward starting interest rate swaps | Cash flow | $ | $ | 2024-2034 | Accounts payable and accrued liabilities | ||||||||||||
Forward starting interest rate collars | Cash flow | 2024 | Accounts payable and accrued liabilities | ||||||||||||||
CAD term loan | Net investment | 2024 | Term loans, net | ||||||||||||||
$ | $ | ||||||||||||||||
(Loss) Gain Recognized in Other Comprehensive (Loss) Income | ||||||||||
Three Months Ended March 31, | ||||||||||
2020 | 2019 | Income Statement Location | ||||||||
Cash Flow Hedges: | ||||||||||
Interest rate products | $ | ( | ) | $ | ( | ) | Interest expense | |||
Net Investment Hedges: | ||||||||||
Foreign currency products | ( | ) | N/A | |||||||
CAD term loan | ( | ) | N/A | |||||||
$ | ( | ) | $ | ( | ) | |||||
Gain Reclassified from Accumulated Other Comprehensive Income into Income | ||||||||||
Three Months Ended March 31, | ||||||||||
2020 | 2019 | Income Statement Location | ||||||||
Cash Flow Hedges: | ||||||||||
Interest rate products | $ | $ | Interest expense | |||||||
As of March 31, 2020 | ||||||||||||||||||||||||
Gross Amounts of Recognized Assets / Liabilities | Gross Amounts Offset in the Balance Sheet | Net Amounts of Assets / Liabilities presented in the Balance Sheet | Gross Amounts Not Offset in the Balance Sheet | |||||||||||||||||||||
Financial Instruments | Cash Collateral Received | Net Amount | ||||||||||||||||||||||
Offsetting Assets: | ||||||||||||||||||||||||
Derivatives | $ | $ | $ | $ | ( | ) | $ | $ | ||||||||||||||||
Offsetting Liabilities: | ||||||||||||||||||||||||
Derivatives | $ | $ | $ | $ | ( | ) | $ | $ | ||||||||||||||||
As of December 31, 2019 | ||||||||||||||||||||||||
Gross Amounts of Recognized Assets / Liabilities | Gross Amounts Offset in the Balance Sheet | Net Amounts of Assets / Liabilities presented in the Balance Sheet | Gross Amounts Not Offset in the Balance Sheet | |||||||||||||||||||||
Financial Instruments | Cash Collateral Received | Net Amount | ||||||||||||||||||||||
Offsetting Assets: | ||||||||||||||||||||||||
Derivatives | $ | $ | $ | $ | ( | ) | $ | $ | ||||||||||||||||
Offsetting Liabilities: | ||||||||||||||||||||||||
Derivatives | $ | $ | $ | $ | ( | ) | $ | $ | ||||||||||||||||
March 31, 2020 | December 31, 2019 | ||||||||||||||||||||||
Face Value (1) | Carrying Amount (2) | Fair Value | Face Value (1) | Carrying Amount (2) | Fair Value | ||||||||||||||||||
Financial assets: | |||||||||||||||||||||||
Loans receivable | $ | $ | $ | $ | $ | $ | |||||||||||||||||
Preferred equity investments | |||||||||||||||||||||||
Financial liabilities: | |||||||||||||||||||||||
Senior Notes | |||||||||||||||||||||||
Secured indebtedness |
(1) | Face value represents amounts contractually due under the terms of the respective agreements. |
(2) | Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs. |
Fair Value Measurements Using | |||||||||||||||
Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | |||||||||||||
Total | |||||||||||||||
Financial assets: | |||||||||||||||
Loans receivable | $ | $ | $ | $ | |||||||||||
Preferred equity investments | |||||||||||||||
Financial liabilities: | |||||||||||||||
Senior Notes | |||||||||||||||
Secured indebtedness |
Fair Value Measurements Using | |||||||||||
Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | |||||||||
Total | |||||||||||
Recurring Basis: | |||||||||||
Financial assets: | |||||||||||
Forward starting interest rate swaps | |||||||||||
Cross currency interest rate swaps | |||||||||||
Financial liabilities: | |||||||||||
Interest rate swaps | |||||||||||
Forward starting interest rate swaps | |||||||||||
Forward starting interest rate collars |
Declaration Date | Record Date | Amount Per Share | Dividend Payable Date | |||||
February 4, 2020 | February 14, 2020 | $ | February 28, 2020 |
March 31, 2020 | December 31, 2019 | |||||||
Foreign currency translation loss | $ | $ | ( | ) | ||||
Unrealized loss on cash flow hedges | ( | ) | ( | ) | ||||
Total accumulated other comprehensive loss | $ | ( | ) | $ | ( | ) | ||
Three Months Ended March 31, | ||||||||
2020 | 2019 | |||||||
Numerator | ||||||||
Net income (loss) attributable to common stockholders | $ | $ | ( | ) | ||||
Denominator | ||||||||
Basic weighted average common shares and common equivalents | ||||||||
Dilutive restricted stock units | ||||||||
Diluted weighted average common shares | ||||||||
Net income (loss) attributable to common stockholders, per: | ||||||||
Basic common share | $ | $ | ( | ) | ||||
Diluted common share | $ | $ | ( | ) | ||||
• | Any sale of the subsidiary guarantor or of all or substantially all of its assets; |
• | A merger or consolidation of the subsidiary guarantor with the Operating Partnership or the Company, provided that the surviving entity remains a guarantor; |
• | The requirements for legal defeasance or covenant defeasance or to discharge the indentures governing the 2024 Notes have been satisfied; |
• | A liquidation or dissolution, to the extent permitted under the indenture governing the 2024 Notes, of the subsidiary guarantor; |
• | The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty; or |
• | If the subsidiary guarantor is not a guarantor or is not otherwise liable in respect of any obligations under any credit facility (as defined in the indenture governing the 2024 Notes) of the Company or any of its subsidiaries. |
• | A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes; |
• | A merger or consolidation, provided that the surviving entity remains a guarantor; or |
• | The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied. |
March 31, 2020 | December 31, 2019 | |||||||
Total assets | $ | $ | ||||||
Total liabilities | ||||||||
Three Months Ended March 31, 2020 | ||||||||
Total revenues | ||||||||
Total expenses | ||||||||
Net loss | ( | ) | ||||||
Net loss attributable to common stockholders | ( | ) | ||||||
• | Overview |
• | Critical Accounting Policies |
• | Recently Issued Accounting Standards Update |
• | Results of Operations |
• | Liquidity and Capital Resources |
• | Concentration of Credit Risk |
• | Skilled Nursing Facility Reimbursement Rates |
• | Obligations and Commitments |
• | Off-Balance Sheet Arrangements |
• | Decreased occupancy and increased operating costs for our tenants and borrowers, which may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to us. In some cases, we may have to restructure tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. |
• | Decreased occupancy and increased operating costs within our Senior Housing - Managed portfolio and in our 49% equity interest in a joint venture with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, that owns senior housing communities managed by Enlivant (the “Enlivant Joint Venture”), which may negatively impact the operating results of these investments. Prolonged deterioration in the operating results for these investments could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. |
Three Months Ended March 31, | Increase / (Decrease) | Percentage Difference | Variance due to Acquisitions, Originations and Dispositions (1) | Remaining Variance (2) | ||||||||||||||||||
2020 | 2019 | |||||||||||||||||||||
Revenues: | ||||||||||||||||||||||
Rental and related revenues | $ | 106,512 | $ | 116,387 | $ | (9,875 | ) | (8 | )% | $ | (4,050 | ) | $ | (5,825 | ) | |||||||
Interest and other income | 2,851 | 3,325 | (474 | ) | (14 | )% | (570 | ) | 96 | |||||||||||||
Resident fees and services | 39,983 | 17,061 | 22,922 | 134 | % | 2,280 | 20,642 | |||||||||||||||
Expenses: | ||||||||||||||||||||||
Depreciation and amortization | 44,168 | 44,949 | (781 | ) | (2 | )% | (1,661 | ) | 880 | |||||||||||||
Interest | 25,704 | 36,318 | (10,614 | ) | (29 | )% | — | (10,614 | ) | |||||||||||||
Triple-net portfolio operating expenses | 4,901 | 5,289 | (388 | ) | (7 | )% | (124 | ) | (264 | ) | ||||||||||||
Senior housing - managed portfolio operating expenses | 27,261 | 12,040 | 15,221 | 126 | % | 1,947 | 13,274 | |||||||||||||||
General and administrative | 8,761 | 8,184 | 577 | 7 | % | — | 577 | |||||||||||||||
Provision for loan losses and other reserves | 667 | 1,207 | (540 | ) | (45 | )% | — | (540 | ) | |||||||||||||
Impairment of real estate | — | 103,134 | (103,134 | ) | NM | (97,105 | ) | (6,029 | ) | |||||||||||||
Other income (expense): | ||||||||||||||||||||||
Other income | 2,259 | 171 | 2,088 | 1,221 | % | — | 2,088 | |||||||||||||||
Net loss on sales of real estate | (217 | ) | (1,520 | ) | 1,303 | (86 | )% | 1,303 | — | |||||||||||||
Loss from unconsolidated joint venture | (3,667 | ) | (1,383 | ) | (2,284 | ) | 165 | % | (1,729 | ) | (555 | ) | ||||||||||
Income tax expense | (1,042 | ) | (612 | ) | (430 | ) | 70 | % | — | (430 | ) |
(1) | Represents the dollar amount increase (decrease) for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 as a result of investments/dispositions made after January 1, 2019. |
(2) | Represents the dollar amount increase (decrease) for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 that is not a direct result of investments/dispositions made after January 1, 2019. |
Three Months Ended March 31, | |||||||
2020 | 2019 | ||||||
Net income attributable to common stockholders | $ | 35,217 | $ | (77,704 | ) | ||
Depreciation and amortization of real estate assets | 44,168 | 44,949 | |||||
Depreciation and amortization of real estate assets related to noncontrolling interest | — | (40 | ) | ||||
Depreciation and amortization of real estate assets related to unconsolidated joint venture | 5,585 | 5,316 | |||||
Net loss on sales of real estate | 217 | 1,520 | |||||
Net loss on sales of real estate related to unconsolidated joint venture | 1,729 | — | |||||
Impairment of real estate | — | 103,134 | |||||
FFO attributable to common stockholders | 86,916 | 77,175 | |||||
Merger and acquisition costs | 159 | 6 | |||||
Stock-based compensation expense | 2,360 | 2,775 | |||||
Non-cash rental and related revenues | (365 | ) | (1,164 | ) | |||
Non-cash interest income | (561 | ) | (562 | ) | |||
Non-cash interest expense | 2,233 | 2,561 | |||||
Provision for loan losses and other reserves | 667 | 1,207 | |||||
Other non-cash adjustments related to unconsolidated joint venture | 539 | 1,115 | |||||
Other non-cash adjustments | (106 | ) | 52 | ||||
AFFO attributable to common stockholders | $ | 91,842 | $ | 83,165 | |||
FFO attributable to common stockholders per diluted common share | $ | 0.42 | $ | 0.43 | |||
AFFO attributable to common stockholders per diluted common share | $ | 0.44 | $ | 0.46 | |||
Weighted average number of common shares outstanding, diluted: | |||||||
FFO attributable to common stockholders | 206,006,285 | 178,936,854 | |||||
AFFO attributable to common stockholders | 206,509,513 | 179,709,444 | |||||
Three Months Ended March 31, | |||||||||||||||||||||||
2020 | 2019 | 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||
Net Income | FFO | AFFO | |||||||||||||||||||||
Rental and related revenues: | |||||||||||||||||||||||
Reduction of revenues related to non-cash receivable / lease intangible write-offs | $ | 6.1 | $ | 5.9 | $ | 6.1 | $ | 5.9 | $ | — | $ | — | |||||||||||
Senior housing - managed portfolio operating expenses | |||||||||||||||||||||||
COVID-19 pandemic related expenses | 0.3 | — | 0.3 | — | 0.3 | — | |||||||||||||||||
General and administrative expense: | |||||||||||||||||||||||
CCP transition expenses | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
Merger and acquisition costs | 0.2 | — | 0.2 | — | — | — | |||||||||||||||||
Provision for doubtful accounts | 0.7 | 1.2 | 0.7 | 1.2 | — | — | |||||||||||||||||
Other income | 2.3 | 0.2 | 2.3 | 0.2 | 2.1 | 0.2 | |||||||||||||||||
Loss from unconsolidated joint venture: | |||||||||||||||||||||||
Deferred income tax expense | 0.2 | 0.4 | 0.2 | 0.4 | — | — | |||||||||||||||||
COVID-19 pandemic related expenses | 0.5 | — | 0.5 | — | 0.5 | — | |||||||||||||||||
Interest Rate Type | Principal Balance as of March 31, 2020 (1)(2) | Principal Balance as of December 31, 2019 (1) | Weighted Average Interest Rate at March 31, 2020 (3) | Maturity Date | |||||||||
Fixed Rate | $ | 98,362 | $ | 114,777 | 3.47 | % | December 2021 - August 2051 |
(1) | Principal balance does not include deferred financing costs, net of $1.3 million and $1.7 million as of March 31, 2020 and December 31, 2019, respectively. |
(2) | Excludes $14.2 million principal balance secured by two skilled nursing/transitional care facilities classified as held for sale as of March 31, 2020. See Note 5, “Impairment of Real Estate, Assets Held for Sale and Dispositions,” in the Notes to Condensed Consolidated Financial Statements for additional information. |
(3) | Weighted average interest rate includes private mortgage insurance. |
April 1 through December 31, 2020 | Year Ending December 31, | ||||||||||||||||||||||||||
Total | 2021 | 2022 | 2023 | 2024 | After 2024 | ||||||||||||||||||||||
Secured indebtedness (1) | $ | 135,590 | $ | 4,692 | $ | 20,193 | $ | 5,196 | $ | 5,196 | $ | 5,196 | $ | 95,117 | |||||||||||||
Revolving Credit Facility (2) | 117,110 | 3,524 | 4,678 | 4,678 | 104,230 | — | — | ||||||||||||||||||||
Term Loans (3) | 1,153,492 | 19,808 | 28,838 | 132,974 | 372,770 | 599,102 | — | ||||||||||||||||||||
Senior Notes (4) | 1,665,754 | 46,584 | 59,055 | 59,055 | 59,055 | 359,055 | 1,082,950 | ||||||||||||||||||||
Operating leases | 2,773 | 320 | 445 | 467 | 507 | 529 | 505 | ||||||||||||||||||||
Total | $ | 3,074,719 | $ | 74,928 | $ | 113,209 | $ | 202,370 | $ | 541,758 | $ | 963,882 | $ | 1,178,572 |
(1) | Secured indebtedness includes principal payments and interest payments through the applicable maturity dates. Total interest on secured indebtedness, based on contractual rates, is $37.2 million, which is attributable to fixed rate debt. |
(2) | Revolving Credit Facility includes interest payments and payments related to the facility fee due to the lenders based on the amount of commitments under the Revolving Credit Facility through the maturity date (assuming no exercise of our two six-month extension options) totaling $16.1 million. |
(3) | Term Loans includes interest payments through the applicable maturity dates totaling $110.3 million, which reflects the impact of interest rate swaps. |
(4) | Senior Notes includes interest payments through the applicable maturity dates totaling $415.8 million. |
• | Decreased occupancy and increased operating costs (including costs due to the implementation of additional safety protocols and procedures, purchases of personal protective equipment (PPE), increased staffing to allow facilities to adhere to social distancing and infection control protocols, premium pay and incentive pay for the staff) for our tenants and borrowers, which may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to us. In some cases, we may have to restructure tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. |
• | Decreased occupancy and increased operating costs (including costs due to the implementation of additional safety protocols and procedures, purchases of personal protective equipment (PPE), increased staffing to allow facilities to adhere to social distancing and infection control protocols, premium pay and incentive pay for the staff) within our Senior Housing - Managed portfolio and in our Enlivant Joint Venture, which may negatively impact the operating results of these investments. Prolonged deterioration in the operating results for these investments could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. |
Ex. | Description | |
2.1 | ||
3.1 | ||
3.1.1 | ||
3.2 | ||
31.1* | ||
31.2* | ||
32.1** | ||
32.2** | ||
101.INS* | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
101.SCH* | XBRL Taxonomy Extension Schema Document. | |
101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document. | |
101.DEF* | XBRL Taxonomy Extension Definition Linkbase Document. | |
101.LAB* | XBRL Taxonomy Extension Label Linkbase Document. | |
101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document. | |
104* | Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
* | Filed herewith. |
** | Furnished herewith. |
SABRA HEALTH CARE REIT, INC. | ||
Date: May 6, 2020 | By: | /S/ RICHARD K. MATROS |
Richard K. Matros | ||
Chairman, President and | ||
Chief Executive Officer | ||
(Principal Executive Officer) | ||
Date: May 6, 2020 | By: | /S/ HAROLD W. ANDREWS, JR. |
Harold W. Andrews, Jr. | ||
Executive Vice President, | ||
Chief Financial Officer and Secretary | ||
(Principal Financial and Accounting Officer) |
1. | I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
/S/ RICHARD K. MATROS |
Richard K. Matros |
Chairman, President and Chief Executive Officer |
1. | I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
/S/ HAROLD W. ANDREWS, JR. |
Harold W. Andrews, Jr. |
Executive Vice President, Chief Financial Officer and Secretary |
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
/S/ RICHARD K. MATROS |
Richard K. Matros |
Chairman, President and Chief Executive Officer |
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
/S/ HAROLD W. ANDREWS, JR. |
Harold W. Andrews, Jr. |
Executive Vice President, Chief Financial Officer and Secretary |
SUBSEQUENT EVENTS |
3 Months Ended |
---|---|
Mar. 31, 2020 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued. Dividend Declaration On May 6, 2020, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on May 29, 2020 to common stockholders of record as of the close of business on May 18, 2020.
|
LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Receivable and Other Investments | As of March 31, 2020 and December 31, 2019, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
(1) Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in Accretable Yield of Loans with Deteriorated Credit Quality | The following table presents changes in the accretable yield for the three months ended March 31, 2020 and 2019 (in thousands):
|
EQUITY - Common Stock (Details) - USD ($) |
3 Months Ended | ||
---|---|---|---|
Dec. 11, 2019 |
Mar. 31, 2020 |
Mar. 31, 2019 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Tax withholding obligations incurred on behalf of employees | $ 900,000 | $ 1,300,000 | |
Restricted Stock Units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares issued upon vesting (in shares) | 161,338 | ||
ATM Program | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Aggregate gross proceeds possible from sales of common stock under equity distribution agreement (up to) | $ 400,000,000.0 | ||
Shares sold under the ATM Program (in shares) | 200,000 | ||
Sale of stock, average price per share (in dollars per share) | $ 20.33 | ||
Gross proceeds from issuance of common stock | $ 3,900,000 | ||
Payments for stock issuance commissions | 58,000 | ||
Amount available under ATM Program | $ 336,100,000 |
EARNINGS PER COMMON SHARE - Narrative (Details) - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2020 |
Mar. 31, 2019 |
|
Restricted Stock Units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive securities not included in computation of diluted earnings per share (in shares) | 6,300 | 3,100 |
DEBT - Secured Debt (Details) $ in Thousands |
Mar. 31, 2020
USD ($)
Property
|
Dec. 31, 2019
USD ($)
|
---|---|---|
Debt Instrument [Line Items] | ||
Deferred financing costs, net | $ 20,553 | |
Assets Held for Sale | Skilled Nursing Transitional Care Facilities | ||
Debt Instrument [Line Items] | ||
Number of properties held for sale | Property | 2 | |
Secured Debt | ||
Debt Instrument [Line Items] | ||
Deferred financing costs, net | $ 1,296 | $ 1,700 |
Secured Debt | Assets Held for Sale | Skilled Nursing Transitional Care Facilities | ||
Debt Instrument [Line Items] | ||
Principal balance | 14,200 | |
Deferred financing costs, net | 400 | |
Secured Debt | Fixed Rate | ||
Debt Instrument [Line Items] | ||
Principal balance | $ 98,362 | $ 114,777 |
Weighted average interest rate | 3.47% |
Label | Element | Value |
---|---|---|
Accounting Standards Update 2016-02 [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | $ (32,502,000) |
Accounting Standards Update 2016-02 [Member] | Parent [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | (32,502,000) |
Accounting Standards Update 2016-02 [Member] | Accumulated Distributions in Excess of Net Income [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | (32,502,000) |
Accounting Standards Update 2016-13 [Member] | Parent [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | $ (167,000) |
BUSINESS (Details) |
Mar. 31, 2020 |
Jan. 02, 2018 |
---|---|---|
Enlivant Joint Venture | ||
Schedule of Equity Method Investments [Line Items] | ||
Equity interest in joint venture | 49.00% | 49.00% |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
3 Months Ended |
---|---|
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2020 and December 31, 2019 and for the three month periods ended March 31, 2020 and 2019. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC. GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary. The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2020, the Company determined that it was not the primarily beneficiary of any VIEs. As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2020, none of the Company’s investments in loans were accounted for as real estate joint ventures. As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of March 31, 2020, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Reclassifications Certain amounts in the Company’s condensed consolidated statements of income and condensed consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations. Recently Issued Accounting Standards Update Adopted In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with ASU 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 (collectively, “Topic 326”) on January 1, 2020. The financial assets within the scope of Topic 326 are the Company’s investments in a direct financing lease and loans receivable, including the portion of unfunded loan commitments expected to be funded. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. Upon adoption of these standards, the Company recognized the cumulative effect on the opening balance of the allowance for credit losses in the condensed consolidated balance sheets, which resulted in an increase to cumulative distributions in excess of net income and a decrease to total assets of $0.2 million. Issued but Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2022. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.
|
LOANS RECEIVABLE AND OTHER INVESTMENTS |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LOANS RECEIVABLE AND OTHER INVESTMENTS | LOANS RECEIVABLE AND OTHER INVESTMENTS As of March 31, 2020 and December 31, 2019, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of both March 31, 2020 and December 31, 2019, the Company had four loans receivable investments, with an aggregate principal balance of $2.3 million, that were considered to have deteriorated credit quality. As of March 31, 2020 and December 31, 2019, the book value of the outstanding loans with deteriorated credit quality was $0.7 million and $0.8 million, respectively. The following table presents changes in the accretable yield for the three months ended March 31, 2020 and 2019 (in thousands):
During the three months ended March 31, 2020, the Company increased its allowance for loan losses by $0.7 million. As of March 31, 2020, the Company had a $1.2 million allowance for loan losses. As of March 31, 2020, the Company did not consider any loans receivable investments to be impaired. As of March 31, 2020, two loans receivable investments with no book value were on nonaccrual status. As of March 31, 2020, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status. As of December 31, 2019, the Company had no asset-specific loan loss reserve and a $0.6 million portfolio-based loan loss reserve. As of December 31, 2019, the Company did not consider any loans receivable investments to be impaired. As of December 31, 2019, two loans receivable investments with no book value were on nonaccrual status. As of December 31, 2019, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status. During the three months ended March 31, 2019, the Company recorded a $1.2 million provision for specific loan losses and recorded a $27,000 reduction to its provision for portfolio-based loan losses.
|
EQUITY |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EQUITY | EQUITY Common Stock On December 11, 2019, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. During the three months ended March 31, 2020, the Company sold 0.2 million shares under the ATM Program at an average price of $20.33 per share, generating gross proceeds of $3.9 million, before $58,000 of commissions. As of March 31, 2020, the Company had $336.1 million available under the ATM Program. The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2020:
During the three months ended March 31, 2020, the Company issued 161,338 shares of common stock as a result of restricted stock unit vestings. Upon any payment of shares to employees as a result of restricted stock unit vestings, the employees’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the three months ended March 31, 2020 and 2019, the Company incurred $0.9 million and $1.3 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants. Accumulated Other Comprehensive Loss The following is a summary of the Company’s accumulated other comprehensive loss (in thousands):
|
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2020 |
Mar. 31, 2019 |
|
Statement of Comprehensive Income [Abstract] | ||
Net income (loss) | $ 35,217 | $ (77,692) |
Unrealized gain (loss), net of tax: | ||
Foreign currency translation gain (loss) | 1,707 | (560) |
Unrealized loss on cash flow hedges | (40,692) | (13,488) |
Total other comprehensive loss | (38,985) | (14,048) |
Comprehensive loss | (3,768) | (91,740) |
Comprehensive income attributable to noncontrolling interest | 0 | (12) |
Comprehensive loss attributable to Sabra Health Care REIT, Inc. | $ (3,768) | $ (91,752) |
BUSINESS |
3 Months Ended | ||||||||
---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||
BUSINESS | BUSINESS Overview Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture. COVID-19 Since first being reported in Wuhan, China in December 2019, COVID-19 has spread globally, including to every state in the United States and more than 175 countries. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19. The outbreak has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to control its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business closures, quarantines and shelter-in-place orders. The COVID-19 pandemic and measures to prevent its spread are expected to negatively impact the Company and its operations in its fiscal quarter ending June 30, 2020 and beyond, in a number of ways, including but not limited to:
The Company’s financial results as of and for the three months ended March 31, 2020 reflect the results of the Company’s evaluation of the impact of COVID-19 on its business including, but not limited to, its evaluation of impairments of long-lived assets, measurement of credit losses on financial instruments, evaluation of any lease modifications, estimates of fair value and the Company’s ability to continue as a going concern.
|
RECENT REAL ESTATE ACQUISITIONS - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) - Recent Real Estate Acquisitions $ in Thousands |
Mar. 31, 2020
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Land | $ 4,740 |
Building and improvements | 76,247 |
Total consideration | 83,367 |
Tenant origination and absorption costs intangible assets | |
Business Acquisition [Line Items] | |
Tenant intangible assets | 2,156 |
Tenant relationship intangible assets | |
Business Acquisition [Line Items] | |
Tenant intangible assets | $ 224 |
SUMMARIZED CONDENSED CONSOLIDATING INFORMATION (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Condensed Financial Information Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aggregate Summarized Balance Sheet and Statement of Loss Information | The aggregate summarized balance sheet information as of March 31, 2020 and December 31, 2019 and aggregate summarized statement of loss information for the three months ended March 31, 2020 is as follows (in thousands):
|
EARNINGS PER COMMON SHARE |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EARNINGS PER COMMON SHARE | EARNINGS PER COMMON SHARE The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2020 and 2019 (in thousands, except share and per share amounts):
During the three months ended March 31, 2020 and 2019, approximately 6,300 and 3,100 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive.
|
RECENT REAL ESTATE ACQUISITIONS |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||
RECENT REAL ESTATE ACQUISITIONS | RECENT REAL ESTATE ACQUISITIONS During the three months ended March 31, 2020, the Company acquired two senior housing communities leased to a third party under a triple-net lease and one Senior Housing - Managed community. No acquisitions were completed during the three months ended March 31, 2019. The consideration was allocated as follows (in thousands):
The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-average amortization periods as of the respective dates of acquisition of six years and 25 years, respectively, for acquisitions completed during the three months ended March 31, 2020. For the three months ended March 31, 2020, the Company recognized $2.4 million of total revenues and $0.8 million of net income attributable to common stockholders from the facilities acquired during the three months ended March 31, 2020.
|
DEBT |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DEBT | DEBT Secured Indebtedness The Company’s secured debt consists of the following (dollars in thousands):
Senior Unsecured Notes The Company’s senior unsecured notes consist of the following (dollars in thousands):
The 2024 Notes and the 2029 Notes were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 4.80% and 3.90%, respectively, per annum. Interest is payable semiannually on June 1 and December 1 of each year for the 2024 Notes and on April 15 and October 15 of each year for the 2029 Notes. The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes. The obligations under the 2024 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes and 2029 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances. See Note 12, “Summarized Condensed Consolidating Information,” for additional information concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees. The indentures and agreements (the “Senior Notes Indentures”) governing the 2024 Notes, 2026 Notes, 2027 Notes and 2029 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of March 31, 2020, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures. Credit Agreement On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Credit Agreement”). The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans (of which $955.0 million was outstanding as of March 31, 2020) and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions. The Revolving Credit Facility has a maturity date of September 9, 2023, and includes two six-month extension options. $105.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2022, $350.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2023, and the other Term Loans have a maturity date of September 9, 2024. As of March 31, 2020, there was $101.0 million outstanding under the Revolving Credit Facility and $899.0 million available for borrowing. Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.45% per annum for LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Base Rate. As of March 31, 2020, the interest rate on the Revolving Credit Facility was 2.09%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder. The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that ranges from 0.85% to 1.65% depending on the Debt Ratings. The Company has interest rate swaps that fix the LIBOR portion of the interest rate for $845.0 million of LIBOR-based borrowings under its U.S. dollar Term Loans at a weighted average rate of 1.19% and interest rate swaps that fix the CDOR portion of the interest rate for $125.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a weighted average rate of 1.41%. In addition, CAD $125.0 million of the Canadian dollar Term Loan is designated as a net investment hedge. See Note 8, “Derivative and Hedging Instruments,” for further information. The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a minimum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of March 31, 2020, the Company was in compliance with all applicable financial covenants under the Credit Agreement. Interest Expense The Company incurred interest expense of $25.7 million and $36.3 million during the three months ended March 31, 2020 and 2019, respectively. Interest expense includes non-cash interest expense of $2.2 million and $2.6 million for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020 and December 31, 2019, the Company had $18.6 million and $16.7 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets. Maturities The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2020 (in thousands):
(2) Revolving Credit Facility is subject to two six-month extension options.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting | The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2020 and December 31, 2019 and for the three month periods ended March 31, 2020 and 2019. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC.
|
Variable Interest Entities | GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary. The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2020, the Company determined that it was not the primarily beneficiary of any VIEs. As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2020, none of the Company’s investments in loans were accounted for as real estate joint ventures. As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests.
|
Use of Estimates | The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
|
Reclassifications | Certain amounts in the Company’s condensed consolidated statements of income and condensed consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations.
|
Recently Issued Accounting Standards Update | Adopted In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with ASU 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 (collectively, “Topic 326”) on January 1, 2020. The financial assets within the scope of Topic 326 are the Company’s investments in a direct financing lease and loans receivable, including the portion of unfunded loan commitments expected to be funded. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. Upon adoption of these standards, the Company recognized the cumulative effect on the opening balance of the allowance for credit losses in the condensed consolidated balance sheets, which resulted in an increase to cumulative distributions in excess of net income and a decrease to total assets of $0.2 million. Issued but Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2022. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.
|
Fair Value of Financial Instruments | The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments. Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows: Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 6% to 25% with a weighted average rate of 15% in its fair value calculation. As such, the Company classifies these instruments as Level 3. Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 12% to 15% with a weighted average rate of 12% in its fair value calculation. As such, the Company classifies these instruments as Level 3. Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy. Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2. Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized rates ranging from 3% to 4% with a weighted average rate of 3% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
|
DEBT (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt | The Company’s secured debt consists of the following (dollars in thousands):
(3) Weighted average interest rate includes private mortgage insurance. The Company’s senior unsecured notes consist of the following (dollars in thousands):
(1) Principal balance does not include premium, net of $7.3 million and deferred financing costs, net of $9.2 million as of March 31, 2020 and does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Maturities for Outstanding Debt | The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2020 (in thousands):
(2) Revolving Credit Facility is subject to two six-month extension options.
|
EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) - $ / shares |
3 Months Ended | ||
---|---|---|---|
Feb. 04, 2020 |
Mar. 31, 2020 |
Mar. 31, 2019 |
|
Equity [Abstract] | |||
Common dividends (in dollars per share) | $ 0.45 | $ 0.45 | $ 0.45 |
SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2020 |
Mar. 31, 2019 |
Dec. 31, 2019 |
|
Condensed Financial Statements, Captions [Line Items] | |||
Total assets | $ 6,092,304 | $ 6,069,299 | |
Total liabilities | 2,697,091 | 2,580,839 | |
Total revenues | 149,346 | $ 136,773 | |
Total expenses | 111,462 | 211,121 | |
Net loss | 35,217 | (77,692) | |
Net loss attributable to common stockholders | 35,217 | $ (77,704) | |
Guarantor Subsidiaries | |||
Condensed Financial Statements, Captions [Line Items] | |||
Total assets | 70,689 | 52,597 | |
Total liabilities | 2,378,729 | $ 2,241,501 | |
Total revenues | 12 | ||
Total expenses | 30,349 | ||
Net loss | (30,820) | ||
Net loss attributable to common stockholders | $ (30,820) |
LOANS RECEIVABLE AND OTHER INVESTMENTS - Changes in the Accretable Yield (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2020 |
Mar. 31, 2019 |
|
Certain Loans Acquired in Transfer Not Accounted for as Debt Securities, Accretable Yield Movement Schedule [Roll Forward] | ||
Accretable yield, beginning of period | $ 39 | $ 449 |
Accretion recognized in earnings | (8) | (218) |
Reduction due to payoff | 0 | (33) |
Accretable yield, end of period | $ 31 | $ 198 |
DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) - USD ($) $ in Thousands |
Mar. 31, 2020 |
Dec. 31, 2019 |
---|---|---|
Offsetting Assets: | ||
Gross amounts of recognized assets | $ 8,074 | $ 7,477 |
Gross amounts offset in the balance sheet, assets | 0 | 0 |
Net amounts of assets presented in the balance sheet | 8,074 | 7,477 |
Financial instruments, assets | (8,074) | (544) |
Cash collateral received, assets | 0 | 0 |
Net amount, assets | 0 | 6,933 |
Offsetting Liabilities: | ||
Gross amounts of recognized liabilities | 38,411 | 626 |
Gross amounts offset in the balance sheet, liabilities | 0 | 0 |
Liabilities presented in the balance sheet | 38,411 | 626 |
Financial instruments, liabilities | (8,074) | (544) |
Cash collateral received, liabilities | 0 | 0 |
Net amount, liabilities | $ 30,337 | $ 82 |
IMPAIRMENT OF REAL ESTATE, ASSETS HELD FOR SALE AND DISPOSITIONS |
3 Months Ended |
---|---|
Mar. 31, 2020 | |
Discontinued Operations and Disposal Groups [Abstract] | |
IMPAIRMENT OF REAL ESTATE, ASSETS HELD FOR SALE AND DISPOSITIONS | IMPAIRMENT OF REAL ESTATE, ASSETS HELD FOR SALE AND DISPOSITIONS 2020 Assets Held For Sale As of March 31, 2020, the Company determined that two skilled nursing/transitional care facilities, with an aggregate net book value of $11.3 million and secured debt, net balance of $13.8 million, met the criteria to be classified as assets/liabilities held for sale, and these balances are included in accounts receivable, prepaid expenses and other assets, net and accounts payable and accrued liabilities, respectively, on the condensed consolidated balance sheets. Subsequent to March 31, 2020, the Company completed the sale of the facilities for an aggregate gross sales price of $14.4 million and the proceeds were used to repay the outstanding debt secured by the facilities. Dispositions During the three months ended March 31, 2020, the Company completed the sale of three skilled nursing/transitional care facilities for aggregate consideration, net of closing costs, of $6.8 million. The net carrying value of the assets and liabilities of these facilities was $7.0 million, which resulted in an aggregate $0.2 million net loss on sale. Excluding the net loss on sale and real estate impairment, the Company recognized $0.1 million of net loss and $5,000 of net income during the three months ended March 31, 2020 and 2019, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations. 2019 Impairment of Real Estate During the three months ended March 31, 2019, the Company recognized a $103.1 million real estate impairment, of which $92.2 million related to the 30 Senior Care Centers facilities which were subsequently sold and one additional Senior Care Centers facility, and the remaining $10.9 million related to four additional skilled nursing/transitional care facilities which were subsequently sold. Dispositions During the three months ended March 31, 2019, the Company completed the sale of three skilled nursing/transitional care facilities for aggregate consideration, net of closing costs, of $6.9 million. The net carrying value of the assets and liabilities of these facilities was $8.4 million, which resulted in an aggregate $1.5 million net loss on sale. Excluding the net loss on sale, the Company recognized $0.5 million of net income during the three months ended March 31, 2019 from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.
|
FAIR VALUE DISCLOSURES |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FAIR VALUE DISCLOSURES | FAIR VALUE DISCLOSURES Financial Instruments The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments. Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows: Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 6% to 25% with a weighted average rate of 15% in its fair value calculation. As such, the Company classifies these instruments as Level 3. Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 12% to 15% with a weighted average rate of 12% in its fair value calculation. As such, the Company classifies these instruments as Level 3. Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy. Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2. Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized rates ranging from 3% to 4% with a weighted average rate of 3% in its fair value calculation. As such, the Company classifies these instruments as Level 3. The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2020 and December 31, 2019 whose carrying amounts do not approximate their fair value (in thousands):
The Company determined the fair value of financial instruments as of March 31, 2020 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different. Items Measured at Fair Value on a Recurring Basis During the three months ended March 31, 2020, the Company recorded the following amounts measured at fair value (in thousands):
|
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares |
3 Months Ended | ||
---|---|---|---|
Feb. 04, 2020 |
Mar. 31, 2020 |
Mar. 31, 2019 |
|
Statement of Stockholders' Equity [Abstract] | |||
Common dividends (in dollars per share) | $ 0.45 | $ 0.45 | $ 0.45 |
INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases (Details) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2020
USD ($)
facility
|
Mar. 31, 2019
USD ($)
|
Dec. 31, 2019
USD ($)
facility
|
|
Real Estate Properties [Line Items] | |||
Weighted-average remaining term of operating leases | 8 years | ||
Security deposit liability | $ 10.1 | $ 10.5 | |
Letters of credit deposited | 84.0 | 83.0 | |
Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements | 17.8 | $ 14.3 | |
Variable lease revenue | $ 5.2 | $ 4.2 | |
Minimum | |||
Real Estate Properties [Line Items] | |||
Operating lease expiration term | 1 year | ||
Maximum | |||
Real Estate Properties [Line Items] | |||
Operating lease expiration term | 15 years | ||
Operating Segments | |||
Real Estate Properties [Line Items] | |||
Number of properties | facility | 427 | 429 | |
Senior Housing - Managed Communities | Operating Segments | |||
Real Estate Properties [Line Items] | |||
Number of properties | facility | 47 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands |
Mar. 31, 2020 |
Dec. 31, 2019 |
---|---|---|
Assets | ||
Accumulated depreciation | $ 569,752 | $ 539,213 |
Preferred stock, $.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2020 and December 31, 2019 | ||
Par value (in dollars per share) | $ 0.01 | $ 0.01 |
Shares authorized (in shares) | 10,000,000 | 10,000,000 |
Shares issued (in shares) | 0 | 0 |
Shares outstanding (in shares) | 0 | 0 |
Common stock, $.01 par value; 250,000,000 shares authorized, 205,559,356 and 205,208,018 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively | ||
Par value (in dollars per share) | $ 0.01 | $ 0.01 |
Shares authorized (in shares) | 250,000,000 | 250,000,000 |
Shares issued (in shares) | 205,559,356 | 205,208,018 |
Shares outstanding (in shares) | 205,559,356 | 205,208,018 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Thousands |
Mar. 31, 2020
USD ($)
variable_interest_entity
Investment
|
Jan. 01, 2020
USD ($)
|
Dec. 31, 2019
USD ($)
|
---|---|---|---|
Accounting Policies [Line Items] | |||
Number of investments in loans accounted for as real estate joint ventures | Investment | 0 | ||
Total assets | $ 6,092,304 | $ 6,069,299 | |
Topic 326 | |||
Accounting Policies [Line Items] | |||
Cumulative effect of ASU adoption | $ (167) | ||
Total assets | (200) | ||
Topic 326 | Cumulative Distributions in Excess of Net Income | |||
Accounting Policies [Line Items] | |||
Cumulative effect of ASU adoption | $ (167) | ||
Primary Beneficiary | |||
Accounting Policies [Line Items] | |||
Number of variable interest entities | variable_interest_entity | 0 |
EQUITY (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Dividends on Common Stock Declared and Paid | The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2020:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive (Loss) Income | The following is a summary of the Company’s accumulated other comprehensive loss (in thousands):
|
COMMITMENTS AND CONTINGENCIES |
3 Months Ended |
---|---|
Mar. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Environmental As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of March 31, 2020, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations. Legal Matters From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.
|
INVESTMENT IN REAL ESTATE PROPERTIES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Investments, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Properties Held for Investment | The Company’s real estate properties held for investment consisted of the following (dollars in thousands): As of March 31, 2020
As of December 31, 2019
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases | The future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands): As of March 31, 2020
|
FAIR VALUE DISCLOSURES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Face Values, Carrying Amounts and Fair Values of Financial Instruments | The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2020 and December 31, 2019 whose carrying amounts do not approximate their fair value (in thousands):
(2) Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Financial Instruments | The Company determined the fair value of financial instruments as of March 31, 2020 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Items Measured at Fair Value on a Recurring Basis | During the three months ended March 31, 2020, the Company recorded the following amounts measured at fair value (in thousands):
|
BV!'!"5#"IV#J5 D1@(Y$!*D$J.CGK]'1 M9V28JNV=6,BD[6K'
MQOHFSQW8&-D8XYEZ71//[-=7!<.8W-OLTG?1P4!XJ1L(J[9#+FBIA@7AF90%
MF'AS9<&;NTN#%%\!?U:$O=F[76HR_^'NMQI*U(1456BC+O2SK.T?4<:RDNY.
M:43N"&_11VH39JM$MO)8GFO]:!'+ <=E0\@QQ-0NJO+<%:0J?7=(BY0NZT)Q
M93)U'52'5'THJE %,++**NL]J8>"FMUED:J[W> SUEU24]752_YP(TEF#B\N
M=>%%N%VX>K%$!U/^'3L^6;='GG;7DIOW-UQKXHQ.HSM"WQN]^S9J=-WF!\
M/ZK41XFZ=NQ@BZAGH@DSDI5<5U(Y6?DQ:%Q>#*;Z/05YO=E+26#.4U]K!C*]
M,<@7( X*ZOP%11*%B6H1;%\ H<(2/
M:YQKNO=(O"X9FN_Z_0/-S9*6/E&CT$$XPB #/.@ C!8!4!@W#Q6X<=X8*9N]
M-]-'MT'7J.F.A[F]!=_'JC9P$'Q?I>#4<23BV (-!A"E*< D77[J9I_]@_9RO;@9F^](LITC;F2P =*4S KC/TJ!BAWS+ %6^3(_[R
MD#EE6N?G96 NP%R57Y,/()&=HM4^):(/@>7).H6-N[1VC 'LI0(B( Z@"!Y0
MR'G5-:=FE1.9@X?8#F 5]0-/ZF.@H3YB,'ADHIPZ%
MSC3),*1(2Z>D,=002X,96X&@,07MTQL'"S7O3Z$]@Y,TKVN_;WG/+JGC_Y]M
MF%D5/&C*G 16APD,"RKL<>9R'6H[#&;V];D)T"?C=PV#: